MHRA Safety Roundup: March 2026
UKMHRA Safety Roundup: March 2026
Recalling Firm: MHRA
Reason for Recall / Hazard
Summary of the latest safety advice for medicines and medical device users...
Product Description & Identification
Summary of the latest safety advice for medicines and medical device users
Affected Products
MHRA Safety Roundup: March 2026
Additional Source Details
| Field | Value |
|---|---|
| Guid | tag:www.gov.uk,2005:/drug-device-alerts/mhra-safety-roundup-march-2026 |
| Link | https://www.gov.uk/drug-device-alerts/mhra-safety-roundup-march-2026 |
| Pub Date | 2026-03-31T14:01:53+01:00 |
| Extracted category | drugs |
Check Other Products In Your Household
Free ToolsSafety recalls are issued daily across foods, medications, vehicles, and electronics. Use our instant tools to check your home for active safety warnings:
Overview
- Recalling FirmMHRA
- Risk LevelMedicines Recall
- DistributionUnited Kingdom
📢 Share Warning
Alert family and friends to keep them safe. Copy this quick alert message:
🚨 SAFETY ALERT: MHRA - MHRA Safety Roundup: March 2026 Check if your household is affected: https://therecallfile.com/recalls/mhra-safety-roundup-march-2026/UK-MHRA-mhra-safety-roundup-march-2026
Join Alertlist
Get instant email updates whenever critical safety recalls like this are published.
Related Recalls
UKClass 4 Medicines Defect Notification: Neuraxpharm UK Ltd, Tuzulby prolonged-release chewable tablets, EL(26)A/36
Class 4 Medicines Defect Notification: Neuraxpharm UK Ltd, Tuzulby prolonged-release chewable tablets, EL(26)A/36
Neuraxpharm UK Ltd has informed the MHRA of missing safety information in the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SmPC) for certain batches of Tuzulby prolonged r...
AustraliaGLP-1 RAs and rare, but severe, eye disorders
GLP-1 RAs and rare, but severe, eye disorders
Product warnings across the GLP-1 RA class of medicines have been updated due to the potential for these products to cause a rare, but severe, form of eye disorder....
UKClass 4 Medicines Defect Notification: Macarthys Laboratories Ltd T/A Martindale Pharma, Xaggitin XL Prolonged-release Tablets, EL(26)A/35
Class 4 Medicines Defect Notification: Macarthys Laboratories Ltd T/A Martindale Pharma, Xaggitin XL Prolonged-release Tablets, EL(26)A/35
Macarthys Laboratories Ltd T/A Martindale Pharma has notified the MHRA of a manufacturing issue impacting several batches of Xaggitin XL Prolonged-release Tablets, due to the occurrence of incorrect t...